Polycystic Ovarian Syndrome (PCOS) Treatment Market 2028 By Drug Class, Distribution Channel and Geography | The Insight Partners

report image

Polycystic Ovarian Syndrome (PCOS) Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Contraceptives, Anti-Depressants, Insulin Sensitizing Agents, Diuretics, Aromatase Inhibitors, Ornithine Decarboxylase Inhibitors); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00004072 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

[Research Report]


PCOS, or polycystic ovary syndrome, is a hormonal disorder that affects a large percentage of women of childbearing age. PCOS is characterised by irregular or prolonged menstrual cycles, as well as elevated amounts of male hormones. Although there is currently there is no cure for PCOS, various medications are used to regulate the menstrual cycle and manage the symptoms of the disease. The polycystic ovarian syndrome treatment sector is booming owing to an increase in the prevalence of PCOS, increased patient awareness, and increased usage of combination therapy. Furthermore, market market is fueled by easier access to PCOS treatments, rising demand for PCOS drugs, and technological advancements for PCOS diagnosis.


The "Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the polycystic ovarian syndrome (PCOS) treatment market with detailed market segmentation by drug class and distribution channel. The report provides key statistics on the market status of the leading polycystic ovarian syndrome (PCOS) treatment market players and offers key trends and opportunities in the market.


  •   Based on drug class the market is segmented as, contraceptives, anti-depressants, insulin sensitizing agents, diuretics, aromatase inhibitors and ornithine decarboxylase inhibitors.
  •   Based on distribution channel the market is segmented as, hospital pharmacies, retail pharmacies and online pharmacies.



  •   Increasing prevalence of PCOS is the key driver for the market growth.
  •   Growing awareness about PCOS and its treatment.
  •   Adoption of combination therapies for PCOS, technological advancements in screening of PCOS.
  •   Extensive R&D efforts to develop effective therapies for treatment of PCOS.


  •   However, lack of specific treatment for PCOS, lack of approved therapeutics are the restraining factors for the market growth.


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The polycystic ovarian syndrome (PCOS) treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the polycystic ovarian syndrome (PCOS) treatment market in these regions.


COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.


The report covers key developments in the polycystic ovarian syndrome (PCOS) treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from polycystic ovarian syndrome (PCOS) treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for polycystic ovarian syndrome (PCOS) treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the polycystic ovarian syndrome (PCOS) treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
  •   Teva Pharmaceutical Industries Ltd.
  •   Mylan N.V.
  •   Sanofi
  •   Novartis AG
  •   Merck KGaA
  •   Bristol-Myers Squibb Company
  •   AstraZeneca
  •   Ferring B.V
  •   Bayer AG
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • The List of Companies

    1. Sanofi
    2. Novartis AG
    3. Teva Pharmaceutical Industries Ltd.
    4. Merck KGaA
    5. Bristol-Myers Squibb Company
    6. AstraZeneca
    8. Mylan N.V
    9. Ferring B.V
    10. Bayer AG
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market

    Have a Question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

    Speak to Analyst
    • $3000
    • $4550
    • $6550
    • $8550

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount